Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 351-358

  Pullen, Joyce ^a   De Rozario, Lindsay ^a   Stolk, Leo M L ^a   Degraeuwe, Pieter L J ^a   Van Tiel, Frank H ^a   Zimmermann, Luc J I ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dosage regimen; Flucloxacillin; Neonates; Population pharmacokinetics

Indexed keywords

CREATININE; FLUCLOXACILLIN; GENTAMICIN;

ARTICLE; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; COVARIANCE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROTEIN BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; FLOXACILLIN; GENTAMICINS; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 33748187021     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211831.96102.91     Document Type: Article

References (34)

1. McGuire W, Clerihew L, Fowlie PW. Infection in the preterm infant. BMJ. 2004;329:1277-1280.
2. Gordon A, Jeffery HE. Antibiotic regimens for suspected late onset sepsis in newborn infants. The Cochrane Database of Systematic Reviews 2005.
3. Janknegt R. The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Pharm World Sci. 1997;19:133-141.
4. Hey E, Hall C. Neonatal Formulary. 4th ed. London: Blackwell BMJ Books; 2003.
5. Adam D, Koeppe P, Heilmann HD. Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g, respectively. Infection. 1983;11:150-154.
6. Thijssen HHW, Wolters J. The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur J Clin Pharmacol. 1982;22:429-434.
7. Røder BL, Frimodt-Møller N, Espersen F, et al. Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection. 1995;23:107-112.
8. Gath J, Charles B, Sampson J, et al. Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients. J Clin Pharmacol. 1995;35:31-36.
9. Herngren L, Ehrnebo M, Broberger U. Pharmacokinetics of free and total flucloxacillin in newborn infants. Eur J Clin Pharmacol. 1987;32:403-409.
10. Adrianzén Vargas MR, Danton MH, Javaid SM, et al. Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant cardiopulmonary bypass surgery. Eur J Cardiothorac Surg. 2004;25:256-260.
11. Guignard J, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics. 1999;103:e49.
12. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther. 1985;38:680-685.
13. Stolk LML, Degraeuwe PLJ, Nieman FHM, et al. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit. 2002;24:527-531.
14. Stolk LML, Degraeuwe PLJ. Gentamicin pharmacokinetics in preterm infants of less than 30 weeks gestational age at birth: effect of postnatal age [abstract]. Br J Clin Pharmacol. 1999;48:767P.
15. Young TE,Mangum B. Neofaxs: A Manual of Drugs Used in Neonatal Care. 17th ed. Raleigh, North Carolina: Acorn Publishing; 2004.
16. Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit. 1994;16:552-559.
17. Thijssen HHW. Analysis of isoxazolyl penicillins and their metabolites in body fluids by high-performance liquid chromatography. J Chromatogr. 1980;183:339-345.
18. Thalhammer F, Maier-Salamon A, Jäger W. Prüfung von stabilität und kompatibilität von flucloxacillin (Floxapens) und ceftazidim (Fortums) in zwei infusionslösungen: relevanz für die klinische praxis. Wien Med Wochenschr. 2005;155:337-343.
19. Proost JH, Meijer DKF. MWPHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155-163.
20. Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet. 2001;40:15-22.
21. Mediware: software for healthcare. Available at: http://www.mediware.nl.
22. Hoog de M, Mouton JW, Anker van den JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-194.
23. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Standard M100-S12. Wayne, Pa: NCCLS; 2002.
24. Bratlid D. Pharmacologic aspects of neonatal hyperbilirubinemia. Birth Defects. 1976;12:184-191.
25. Rolinson GN, Sutherland R. The binding of antibiotics to serum proteins. Br J Pharmacol. 1965;25:638-650.
26. Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17:13-28.
27. Dittert LW, Griffen WO, LaPiana JC, et al. Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration. Antimicrob Agents Chemother. 1969;9:42-48.
28. Nauta EH, Mattie H. Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis. Br J Clin Pharmacol. 1975;2:111-121.
29. Cole M, Kenig MD, Hewitt VA. Metabolism of penicillins to penicilloic acid and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother. 1973;3:463-468.
30. Thijssen HHW, Mattie H. Active metabolites of isoxazolyl penicillins in humans. Antimicrob Agents Chemother. 1976;10:441-446.
31. Pullen J, Stolk LML, Nieman FHM, et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006;28:226-231.
32. 35S-furosemide and its depression by albumin binding. Am J Physiol. 1975;229:93-98.
33. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990;18:20-36.
34. Ehrnebo M, Agurell S, Jalling B, et al. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Europ J Clin Pharmacol. 1971;3:189-193.